Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam for long-term ICU sedation in mechanically ventilated adults with renal failure
NL-OMON57010Recruiting
- Sponsor
- Elisabeth-TweeSteden Ziekenhuis
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of remimazolam and midazolam in critical illness, acute kidney failure (AKF) and kidney failure (2 arms), sponsored by Elisabeth-TweeSteden Ziekenhuis. Primary endpoint: ICU length of stay. Started Oct 2024; status: recruiting.
02
Drugs
remimazolammidazolam
03
Conditions
critical illnessacute kidney failure (AKF)kidney failure
Beyond the preview
Go deeper on NL-OMON57010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57010.